The most important publications in last five years
Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation. Simón-Gracia L, Scodeller P, Fisher WS, Sidorenko V, Steffes VM, Ewert KK, Safinya CR, Teesalu T.ACS Appl Mater Interfaces. 2022 Dec 28;14(51):56613-56622. doi: 10.1021/acsami.2c17961. Epub 2022 Dec 15.PMID: 36521233
Novel Anthracycline Utorubicin for Cancer Therapy.Simón-Gracia L, Sidorenko V, Uustare A, Ogibalov I, Tasa A, Tshubrik O, Teesalu T. Angew Chem Int Ed Engl. 2021 Jul 26;60(31):17018-17027. doi: 10.1002/anie.202016421. Epub 2021 Jun 1. PMID: 33908690
In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues.Pleiko K, Põšnograjeva K, Haugas M, Paiste P, Tobi A, Kurm K, Riekstina U, Teesalu T. Nucleic Acids Res. 2021 Apr 19;49(7):e38. doi: 10.1093/nar/gkaa1279. PMID: 33444445
A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. Balistreri G, Yamauchi Y, Teesalu T. Proc Natl Acad Sci U S A. 2021 Nov 16;118(49):e2112457118. doi: 10.1073/pnas.2112457118. PMID: 34772761
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Österlund P, Joensuu M, Meunier FA, Butcher SJ, Winkler MS, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M. Science. 2020 Nov 13;370(6518):856-860. doi: 10.1126/science.abd2985. Epub 2020 Oct 20. PMID: 33082293
The general assembly of the Estonian Academy of Science selected Pärt Peterson, Professor of Molecular Immunology at the University of Tartu as a member of the academy in the field of biomedicine.
Last week, the US Food and Drug Administration (FDA) approved the world's first vaccine against the chikungunya virus – Ixchiq. The vaccine candidate has been designed and manufactured at the University of Tartu. The human clinical trials were conducted by the biotechnology company Valneva Austria GmbH.
On December 15th Ling Yan will defend a thesis "Stress-associated immune mechanisms of schizophrenia: the importance of region-specific microglia-neurovascular interaction".